



AUTOMATIC CHEMILUMINESCENCE ANALYZER

NOTICE: This brochure is for reference purpose only and subject to change without notic

MACCURA BIOTECHNOLOGY CO., LTD

Add: 8#, 2nd Anhe Road, Hi-tech Zone, 611731 Chengdu Fel: +86 28 8173 1888 E-mail: maccura@maccura.com www.maccura.com





# STABLE FAST CONVENIENT RELIABLE

the magnetic microparticles based, Acridinium Ester (AE) direct chemiluminescence technology. The character of stable performance, fast report, convenient operation and reliable results could make it fully applicable to various application environments of medical laboratories.

The design orientation of i 1000 could not only meet the routine test requirements of medium and small hospitals, but also provide supports to the assay development and STAT tests of large hospitals. The mature compatible system of instrument and reagent, and strict system of metrological traceability could ensure the test results accurate and reliable.





# Stable

Multiple magnetic separation technology, high-efficient B/F separation.

Patented magnetic field design, minimize the magnetic beads' loss.

The track-based technology ensures the accurate sampling of micro-volume.

The needle has the detection function to the liquid level, clot and aspiration failure. The carry-over is less than 0.1ppm.



# Fast

Single-module runs up to 180T/H Time to the first result: 14 minutes

# Convenient

Automatic startup and shutdown Continuous reagents replacement and samples loading during the operation STAT Prioritization, Automatic Rerun Chinese software, easy to learn

# Reliable

Full loaded unattended operation for 4 hours Remote Diagnosis Thorough system of metrological traceability



Cuvettes loading by dumping, one-time for 1200 cuvettes.



Used cuvettes recycling to separate the solid and liquid, which will efficiently reduce the biological safety risks.



30 refrigerated reagent positions, RFID management for reagent info, online reagent replacement.

# i 1000

AUTOMATIC CHEMILUMINESCENCE ANALYZER





STAT samples could be placed randomly and be tested preferentially.



RFID management for activators

Special design to prevent the activators to be placed incorrectly.



Humanized interface design, convenient operation and easy to learn.



# AUTOMATIC CHEMILUMINESCENCE ANALYZER

INFECTIOUS DISEASES

HBsAg		SSA(Ro52)	
HBsAb		SSA(Ro60)	
HBeAg		SSB(La)	
HBeAb		Sm	
HBcAb		Sm/RNP	
HIV Ag/Ab		Scl-70	
anti-TP		Jo-1	
anti-HCV		His	
anti-HAV IgM		AMA-M2	
anti-HBc IgM		CENP-B	
HBV PreS1		Rib-P	
anti-HDV IgM		dsDNA	
anti-HDV IgG		Nuc	
anti-HEV IgM		PCNA	
anti-HEV IgG		PM-Scl	
			CEVILLOPMONIES
	TUMOR MARKERS		SEX HORMONES
	TUMOR MARKERS		SEX HURMUNES
AFP	TUMOR MARKERS	LH	SEX HURMUNES
CEA	TUMOR MARKERS	FSH	SEX HURMUNES
CEA CA125	TUMOR MARKERS	FSH PRL	SEX HURMUNES
CEA CA125 CA15-3	TUMOR MARKERS	FSH PRL Prog	SEX HURMUNES
CEA CA125 CA15-3 CA19-9	TUMOR MARKERS	FSH PRL Prog β-HCG	SEX HURMUNES
CEA CA125 CA15-3 CA19-9 t-PSA	TUMOR MARKERS	FSH PRL Prog β-HCG E2	SEX HURMUNES
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes	SEX HURMUNES
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA NSE	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes AMH	SEX HURMUNES
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA NSE CYFRA21-1	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes AMH 17-0H Prog	SEX HURMUNES
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA NSE CYFRA21-1 SCC	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes AMH 17-0H Prog DHEA-S04	SEX HURMUNES
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA NSE CYFRA21-1 SCC CA50	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes AMH 17-0H Prog	SEX HURMUNES
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA NSE CYFRA21-1 SCC CA50 pro-GRP	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes AMH 17-0H Prog DHEA-S04	SEX HURMUNES
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA NSE CYFRA21-1 SCC CA50 pro-GRP CA242	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes AMH 17-0H Prog DHEA-S04	
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA NSE CYFRA21-1 SCC CA50 pro-GRP CA242 CA72-4	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes AMH 17-0H Prog DHEA-S04	ALLERGY
CEA CA125 CA15-3 CA19-9 t-PSA f-PSA NSE CYFRA21-1 SCC CA50 pro-GRP CA242	TUMOR MARKERS	FSH PRL Prog β-HCG E2 Tes AMH 17-0H Prog DHEA-S04	


	THYROID FUNCTION		TORCH EUGENICS
TSH FT4 TT4 FT3 TT3 anti-TP0 anti-TG TRAb Tg CT		TOXO IgG TOXO IgM Rubella IgG Rubella IgM CMV IgG CMV IgM HSV 2 IgG HSV 1/2 IgG	
	HYPERTENSION		AUTOIMMUNE HEPATOSIS
ALD Renin Corti ACTH Angio-2		AMA-M2 LKM sp100 SLA	
	AUTOIMMUNE DIABETES		PRENATAL SCREENING
IAA GADA ICA IA-2A		AFP uE3 Free β-HCG PAPP-A	
	CARDIAC MARKERS		ANEMIA
CK-MB Tn Myo NT-Pro BNP		Ferr FA VB12	
	AUTOIMMUNE RHEUMATIC DISEASE		INFLAMMATION
anti-CCP RF		PCT IL-6	
	BONE METABOLISM		GLYCOMETABOLISM
25-0H VD PTH		C-P INS	

New assays available soon

# **SPECIFICATIONS**

Performance	Technology: Automatic /single tube Principle: Acridinium Ester (AE) Direct Chemiluminescence immunoassay technology Throughput: 180 Tests/h for one module Time to the first result: 14min
Sample Module	Sample loading capacity: 50, loading with sample racks. Automatic retest, STAT samples could be placed randomly and tested preferentially
Sample Loading System Module	Sample carry-over < 0.1ppm Foam/Clot and Liquid level detection / Volume tracking /Collision-avoidance Sample type: Serum /Plasma /Whole blood /Urine
Reagent Module	30 reagent positions Information management through Radio Frequency Identification Card (RFID) Real-time, onboard mixture of magnetic beads Reagent online replacement
Consumable Module	Loading capacity of cuvettes: 1200 Cuvettes loading by dumping
Detection Module	Reaction temperature: 37°C Mode: Compatible with the common immunoreaction Mixing: Non-contact Stir Magnetic separation: Multiple magnetic separation technology
Function	Operation system: Windows 7 and above Display: LCD touch screen Remote diagnosis system Automatic startup & shutdown Bi-directional communication
Environmental Requirements	Temperature: 10°C-30°C Humidity: 30%-70% Altitude: -200m-3700m







# SARS-CoV-2 IgM (CLIA) SARS-CoV-2 IgG (CLIA)

Compatible with i 3000 and i 1000 automatic chemiluminescence analyzer

SARS-CoV-2 IgM, IgG separate detection Apply to serum and plasma Pretreatment is not required. Response time is 20 minutes Open vial expiry date is up to 35 days

**NOTICE**: This brochure is for reference purpose only and subject to change without notice.

MACCURA BIOTECHNOLOGY CO., LTD.

Add: 8#, 2nd Anhe Road, Hi-tech Zone, 611731 Chengdu Tel: +86 28 8173 1888 E-mail: maccura@maccura.com www.maccura.com

















# SARS-CoV-2 IgM (CLIA) SARS-CoV-2 IgG (CLIA)



# **Clinical evaluation**

lgM	Clinical diagnosis results		Total
+	301	0	301
-	45	321	366
Total	346	321	667

Positive coincidence rate (sensitivity): 86.99% Negative coincidence rate (specificity): 100.00% Total coincidence rate: 93.25% kappa=0.866

lgG	Clinical diagn	Total	
+	333	6	339
-	13	315	328
Total	346	321	667

Positive coincidence rate (sensitivity)96.24% Negative coincidence rate (specificity): 98.13% Total coincidence rate: 97.15% kappa=0.943

# **Application Environment**

# Apply to fever clinic and STAT Suitable for large-scale sample processing



i 1000 Automatic Chemiluminescence Analyzer 180T/H



i 3000 single module Automatic Chemiluminescence Immunoassay System 300T/H



i 3000 Dual-module Automatic Chemiluminescence Immunoassay System 600T/H

# **Product features**

# Safe

Fully closed automatic detection and unattended operation for 4 hours Used samples recycling to separate the solid and liquid to ensure the biosafe

# Convenient

The reaction time is 20 minutes
Pretreatment is not required
Apply to serum and plasma

#### Accurate

Direct chemiluminiscence technology based on AE has been adopted

Patented washing technology to avoid the carry-over

SARS-CoV-2 IgM, IgG separate detection is suitable for Interpretation of results in different modes

Increase optimized recombinant S protein fragments for better prognosis and rehabilitation assessment

# Kit information

Products name	Specifications	Catalog No.
SARS-CoV-2 IgM (CLIA)	2×200 Tests/Box	EIM4408013
SARS-CoV-2 lgG (CLIA)	2×200 Tests/Box	EIM4408014

 $<sup>^{\</sup>ast}$  Kappa>0.75, which means the test result is highly coincident with the clinical diagnosis results.